FTX002600

FTX002600 is a topical small molecule therapeutic candidate developed by Fountain Therapeutics (also known as Green Fountain) for the treatment of various forms of skin atrophy. Identified through the company's proprietary AI-driven platform designed to reverse cellular aging, FTX002600 is being evaluated for age-associated skin atrophy, glucocorticoid-induced skin atrophy, and weight loss-associated skin atrophy (often referred to as "Wegovy Face"). It is also under investigation for the treatment of scleroderma and as a medical aesthetic alternative to traditional dermal fillers or neurotoxins. The compound is frequently developed as a topical combination therapy alongside FTX003059. As of late 2024, FTX002600 is in the preclinical and IND-enabling stages of development.